Exosomes are extracellular vesicles (EVs) originating from endosomes, with sizes ranging from 30 to 150 nanometers. Secreted by nearly all cell types, exosomes play a key role in cell communication by carrying cell-specific proteins, lipids, and nucleic acids that are selectively absorbed by recipient cells.
Recent advancements in exosome technology are driving growth in their application across liquid biopsy, precision medicine, and regenerative medicine. Cancer-derived exosomes, in particular, are valuable for their ability to regulate angiogenesis, metastasis, and immunity, making them crucial for cancer detection, diagnosis, and treatment selection.
Exosome cargos offer prognostic insights for various diseases, including cardiovascular, renal, neurodegenerative, and metabolic disorders, as well as cancer. The discovery of numerous biomolecules within exosomes has spurred extensive research into their use as cancer biomarkers for detection, monitoring, and treatment.
Exosomes are present in many biofluids such as serum, plasma, urine, and saliva, making them ideal for minimally invasive diagnostics. They also serve as prognostic indicators and predictors of treatment responses. Furthermore, exosomes are being investigated for therapeutic use. For instance, exosomes can be engineered to carry therapeutic siRNA or proteins for targeted treatment of diseases caused by defective or missing molecules. Mesenchymal stem cell (MSC) derived exosomes have shown potential in reducing inflammation, preventing scar tissue formation, and modulating immune responses.
The exosome field, once underappreciated, is now rapidly evolving. Recent publications highlight the significant contributions of U.S. authors and Chinese researchers, with Dr. Susanne Gabrielsson from the Karolinska Institutet and Unicyte AG leading in relevant scientific literature.
The global strategic report details the burgeoning exosome market, including trends in patents, grants, publications, and clinical trials. It covers industry partnerships, M&A activities, and financing, with insights into the competitive landscape and market forecasts through 2030.
Exosome-based diagnostics and therapeutics are expanding, with 388 clinical trials currently underway. Although no exosome therapeutics have received marketing approval yet, the first five products are anticipated by 2029. Exosomes offer promising advantages over traditional therapies, including targeted delivery, reduced side effects, and avoidance of immune detection.
In addition to medical applications, exosomes are also being used within cosmetics to promote skin rejuvenation, wound healing, scar revision, and hair restoration. Two exosome-based diagnostics have already received Fast Track approval from the U.S. FDA.
This comprehensive report provides:
- Market analysis for exosome therapeutics, diagnostics, product/services, manufacturing technologies, and cosmetic applications
- The clinical trial pipeline for exosome therapeutics, including both naïve and engineered exosomes
- Approved and forthcoming products leveraging exosome diagnostics
- Clinical trial activity by type, region, phase, and sponsor
- Analysis of key industry metrics, including scientific publications, patents, grants, and clinical trials
- Key funding events, including M&A, financing events, co-development agreements, and IPOs
- Strategic partnerships and competitive insights
- Market size figures, broken down by market segment and geography, with forecasts through 2030
- Industry trends and future directions
This report is designed to inform market competitors who are developing exosome therapeutics, diagnostics, research products, manufacturing technologies, cosmeceuticals, and of course, ready-to-use exosomes. With the competitive nature of the exosome market, this report offers a valuable resource to stay informed and seize opportunities, without spending countless hours on research.
Table of Contents
Companies Mentioned
- Bio
- Abbexa, Ltd.
- AcouSort AB
- Aegle Therapeutics
- Aethlon Medical, Inc.
- Akrivis Health Care Pvt., Ltd.
- AM BioTech
- AMS Biotechnology, Ltd. (AMSBIO)
- AnteAGE
- Aposcience AG
- Aruna Bio
- BENEV Company, Inc. (ExoCoBio)
- BioCat GmbH
- BioFluidica
- Biological Dynamics, Inc.
- Biorbyt, Ltd.
- Bioscience Institute
- Biosynth International, Inc.
- BreStem Therapeutics, Inc.
- Capricor Therapeutics
- Carmine Therapeutics
- Cellarcus Biosciences, Inc.
- Cell Care Therapeutics
- Cells for Cells
- Cell Guidance Systems, Ltd.
- Ciloa
- ConvEyXO
- Craif, Inc.
- Creative Bioarray
- Creative Biostructure
- Creative Biolabs
- Creative Medical Technology Holdings, Inc.
- Creative Proteomics
- CUSABIO Technology LLC
- Diadem Biotherapeutics
- Direct Biologics
- Elevai Labs, Inc.
- Entelexo Biotherapeutics
- EriVan Bio
- EVerZom
- Evolutionary Biologics, Inc.
- Evomic Science LLC
- Evox Therapeutics, Ltd.
- EXO Biologics
- ExoCan Healthcare Technologies Pvt., Ltd.
- Exocel Bio
- Exogenus Therapeutics
- Exokeryx, Inc.
- ExoProTher Medical
- ExoQure
- EXORPHIA, Inc.
- ExosomeDx (biotechne)
- ExosomePlus
- Exosome Sciences
- ExoStemTech Co., Ltd.
- ExoVectory
- ExSURE Pvt. Ltd.
- Florica Therapeutics
- HansaBioMed Life Sciences, Ltd.
- ILIAS Biologics, Inc.
- INEXOPLAT, Inc.
- Innocan Pharma
- Innovex Therapeutics, SL
- INOVIQ, Ltd.
- Irazu Oncology
- Izon Science, Ltd.
- Kimera Labs, Inc.
- Leading Biology, Inc.
- LifeSpan Biosciences, Inc.
- Lonza Group, Ltd.
- Mantra Bio
- Mercury Bio
- Mercy Bioanalytics
- Micregen, Ltd.
- Microgentas
- miR Scientific
- Mursla Bio
- MyBioSource, Inc.
- Nano 24 (OBCDCT24)
- NanoSomiX, Inc.
- Nanovex Biotechnologies
- NeurExo Sciences
- NeuroDex, Inc.
- Norgen Biotek Corporation
- Novaxomx GmbH
- Novus Biologicals
- NurExone Biologic, Inc.
- Oasis Diagnostics Corporation
- NX Prenatal, Inc.
- OmniSpirant Therapeutics
- OncoXome, Inc.
- Paracrine Therapeutics Pte, Ltd.
- QIAGEN
- Reactive Medical Labs
- ReNeuron
- RION Aesthetics, Inc.
- Rivela Diagnostics
- RoosterBio, Inc.
- ShiftBIO
- SOL Bio Corporation
- SomesTech
- Stem Cell Medicine, Ltd.
- System Biosciences
- Theoria Science, Inc.
- TheraXyte
- Thermo Fisher Scientific
- TheraXyte Bioscience
- The Tiny Cargo Company
- TransGen Biotech, Co., Ltd.
- Tymora Analytical
- Unicyte AG
- Urvogelbio Pvt, Ltd.
- Versatope Therapeutics
- VesiCURE Therapeutics
- Vesigen Therapeutics, Inc.
- VivaZome Therapeutics
- ZEO ScientifiX, Inc.
Methodology
The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.
Input Sources
- Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
- Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
- Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
- Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
- Product Launch Announcements (Trade Journals, Google News)
- Industry Events (Google News, Google Alerts, Press Releases)
- Company News (SEC Filings, Investor Publications, Historical Performance)
- Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
- Interviews with Stem Cell Industry Leaders
Research & Analysis Methodologies
The publisher employs the following techniques for deriving its market research:
- Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
- Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
- Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
- Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
- Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
- Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
- Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).
LOADING...